

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 March 2020 (05.03.2020)



(10) International Publication Number
WO 2020/043152 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) A61K 39/00 (2006.01)
C07K 19/00 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2019/103215

(22) International Filing Date:

29 August 2019 (29.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/103050

29 August 2018 (29.08.2018) CN

PCT/CN2019/083918

23 April 2019 (23.04.2019) CN

(71) Applicant: NANJING LEGEND BIOTECH CO., LTD.

[CN/CN]; No. 6 Building of Nanjing Life Science Town,
No. 568 Longmian Avenue, Jiangning District, Nanjing,
Jiangsu 211100 (CN).

(72) Inventors: DAI, Qing; Room 204, No. 10 Building, Chun-

huijiayuan, Jiangning District, Nanjing, Jiangsu 211100
(CN). LIU, Jian; Room 1307, Building 16, Wending
Yayuan, Yushu Road, Jiangning District, Nanjing, Jiang-
su 211100 (CN). YANG, Shuai; Room 203, Building 10,
Lander East County Yingxiayuan, 228 Tianyuan East Road,
Moling Street, Jiangning District, Nanjing, Jiangsu 211100
(CN). JIANG, Kun; Room 301, Building 9, Aiqinwan,
No. 1199, Hebin Road, Jiangning District, Nanjing, Jiangsu
211100 (CN). PENG, Yuanyuan; Room 301, Building 9,
Aiqinwan, No. 1199, Hebin Road, Jiangning District, Nan-
jing, Jiangsu 211100 (CN). HU, Chen; Room 806, Build-
ing 12, 9 Longji Road, Jiangning District, Nanjing, Jiang-
su 211100 (CN). WU, Shu; Room 501, Building 3, Huayu
Court, 28 Chengxu Road, Moling Street, Jiangning District,
Nanjing, Jiangsu 211100 (CN).

(74) Agent: CHENG & PENG INTELLECTUAL PROPER-

TY LAW OFFICE; 704, Block B, Xinyu Commercial
Building, 90 Guangqumen Inner Street, Dongcheng Dis-
trict, Beijing 100062 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/043152 A1

(54) Title: ANTI-MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND USES THEREOF

(57) Abstract: Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor- β receptor II (dnTGF β RII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).